Exposure of SUDHL16 and OCI-LY10 cells to CFZ results in a marked decrease in chymotrypsin-like proteasomal activity, an event that is not potentiated by vorinostat
| . | Chymotrypsin-like proteasome activity, RLU/5 μg of protein . | |||
|---|---|---|---|---|
| Treatment . | SUDHL16 . | Percentage inhibition . | OCI-LY10 . | Percentage inhibition . |
| Control | 232 ± 2.4 | — | 198 ± 2.2 | — |
| CFZ | 26 ± 1.6 | 88 | 45 ± 2.5 | 77 |
| Vorinostat | 223 ± 1.7 | 4 | 194 ± 1.2 | 2 |
| CFZ plus vorinostat | 24 ± 1.1 | 89* | 44 ± 2.1 | 77* |
| . | Chymotrypsin-like proteasome activity, RLU/5 μg of protein . | |||
|---|---|---|---|---|
| Treatment . | SUDHL16 . | Percentage inhibition . | OCI-LY10 . | Percentage inhibition . |
| Control | 232 ± 2.4 | — | 198 ± 2.2 | — |
| CFZ | 26 ± 1.6 | 88 | 45 ± 2.5 | 77 |
| Vorinostat | 223 ± 1.7 | 4 | 194 ± 1.2 | 2 |
| CFZ plus vorinostat | 24 ± 1.1 | 89* | 44 ± 2.1 | 77* |
SUDHL16 cells were treated with 3.0nM CFZ with or without 0.75μM vorinostat, or OCI LY10 cells were treated with 7.0nM CFZ with or without 1.5μM vorinostat for one hour. After treatment, cells were collected, and chymotrypsin-like proteasomal activity was monitored as described in “Proteasome inhibition assays.” Values represent the mean plus or minus SD for experiments performed in triplicate on three separate occasions.
CFZ indicates carfilzomib; and —, not applicable.
Not significantly different from values for cells exposed to CFZ alone (P > .05).